185 IBD patients underwent fecal and serum sampling prior to induction with anti-TNF, ustekinumab or vedolizumab therapy.33 Using microbiota profile modeling, two distinct bacterial metacommunities were identified and predicted response to therapy. The gene discussed is TNF; the disease is inflammatory bowel disease.